Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Richardson PG, et al. Among authors: facon t. Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16. Br J Haematol. 2009. PMID: 19170677 Free article. Clinical Trial.
Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C. Harousseau JL, et al. Among authors: facon t. Blood. 1992 Jun 1;79(11):2827-33. Blood. 1992. PMID: 1350228 Free article.
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Moreau P, et al. Among authors: facon t. J Clin Oncol. 1997 Feb;15(2):660-6. doi: 10.1200/JCO.1997.15.2.660. J Clin Oncol. 1997. PMID: 9053491 Clinical Trial.
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau JL. Moreau P, et al. Among authors: facon t. Br J Haematol. 1998 Jun;101(4):766-9. doi: 10.1046/j.1365-2141.1998.00772.x. Br J Haematol. 1998. PMID: 9674753 Free article.
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, De Waele M, Pigneux A, Méresse V, Clark P, Reiffers J. Facon T, et al. Blood. 1999 Aug 15;94(4):1218-25. Blood. 1999. PMID: 10438709 Free article. Clinical Trial.
P53 deletion is not a frequent event in multiple myeloma.
Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R. Avet-Loiseau H, et al. Among authors: facon t. Br J Haematol. 1999 Sep;106(3):717-9. doi: 10.1046/j.1365-2141.1999.01615.x. Br J Haematol. 1999. PMID: 10468863 Free article.
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.
Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Bladé J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L; European Group for Blood and Marrow Transplantation. Gahrton G, et al. Among authors: facon t. Br J Haematol. 2001 Apr;113(1):209-16. doi: 10.1046/j.1365-2141.2001.02726.x. Br J Haematol. 2001. PMID: 11360893 Free article.
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: facon t. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.
426 results